Related articles

• Randomized Controlled Trial

  Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial.

  Lancet Respir Med. 2014 Jan 1;2(1):63-72.

• Randomized Controlled Trial

  The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale.

  Am. Heart J. 2012 Nov 1;164(5):646-653.e3.

• Randomized Controlled Trial

  Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.

  JACC Cardiovasc Imaging. 2012 Sep 1;5(9):911-22.

Show more related articles...